drugset
drugset / Trial / NCT06801236

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236 ↗

Phase 1 Recruiting 67 enrolled Acerand Therapeutics (Hong Kong) Limited
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Timeline

Start
2025-05-12
Primary completion
2028-03-01
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ACE-232 Unknown — Oral

Indications

castration-resistant prostate carcinoma prostate adenocarcinoma